NBIX: Neurocrine Biosciences, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

SummaryFactSheetFinancial
Price
$134.07
Loss Chance
42.3%
6.62JITTA SCORE
18.12%Over Jitta Line
Jitta Ranking
Biotechnology
12 / 282
Health Care
38 / 717
United States
?
423 / 4,223
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
ADMA Biologics
NASDAQ:ADMA
5.32
$10.31
39.07%
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
1.83
$5.28
73.65%
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
1.83
$5.28
73.65%
BioCryst Pharmaceuticals
NASDAQ:BCRX
4.62
$9.20
68.84%
BioMarin Pharmaceutical
NASDAQ:BMRN
6.75
$55.46
9.17%
Jitta Factors
Growth Opportunity (57)
Recent Business Performance (63)
Financial Strength (90)
Return to Shareholders (49)
Competitive Advantage (84)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 3 years
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Debt LevelLow Long Term Debt
Return on EquityConsistently High
CapExVery Low
SG&A to SalesDecreasing Every Year
Operating MarginDeclined
Key Stats
Jitta Score
Jitta Line
6.62
18.12%
2.24
183.94%
3.07
432.53%
Biotechnology
5.32
39.07%
1.82
73.65%
1.82
73.65%
COMPANY DESCRIPTION
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
www.neurocrine.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.